Clinical Trials
20 trialsNCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT05952557 2026-05-28
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT06492616 2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT07287098 2026-05-22
preEMBER
Eli Lilly and Company
Phase 2 Not yet recruiting
NCT07349069 2026-05-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT06979596 2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05774951 2026-05-08
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
NCT05306340 2026-04-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT05780567 2026-04-17
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT06440967 2026-04-06
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT05161195 2026-04-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
NCT05514054 2026-04-02
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT02747004 2026-02-06
Next MONARCH 1
Eli Lilly and Company
Phase 2 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04906395 2026-01-13
OVELIA
Tolmar Inc.
Phase 3 Active not recruiting
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT06449027 2025-10-01
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05128773 2025-09-16
AMEERA-6
Sanofi
Phase 3 Terminated